

**GRAY
PLANT
MOOTY**

500 IDS CENTER
80 SOUTH EIGHTH STREET
MINNEAPOLIS, MN 55402-3796
612 632-3000
Fax: 612 632-4444

1010 WEST ST. GERMAIN STREET
SUITE 600
ST. CLOUD, MN 56301

320 252-4414
Fax: 320 252-4482

Reply to Minneapolis
Peter Forrest
612 632-3067
peter.forrest@gpmlaw.com

1623/\$

FIRST CLASS MAIL
VIA FACSIMILE

April 16, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In re application of: Frey II, William H. *et. al.*
Application No.: 09/844,450
Filed: April 27, 2001
Title: METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR
FUNCTION THROUGH PROTECTION OF TISSUE COMPONENTS
Group Art Unit: 1623
Attorney Docket No.: 83935

TRANSMITTAL LETTER

Dear Sir:

Enclosed for filing with the United States Patent and Trademark Office, please find:

1. Transmittal Letter, including Certificate of First Class Mailing under 37 C.F.R. 1.8;
2. Information Disclosure Statement under 37 CFR §1.97(b);
3. Information Disclosure Statement by Applicant (Form PTP/SB/08B);
4. Copies of all cited references; and,
5. A postage-paid return postcard itemizing the above documents.

Please charge Deposit Account 50-0937 \$180.00 for the Information Disclosure filing fees and for any other fees required at this time. If you have any questions, please contact me.

Very truly yours,

Peter Forrest (33,235)
Attorney for Applicants

Certificate of First Class Mailing under 37 C.F.R. §1.8

I hereby certify that the following identified correspondence is being with sufficient postage for First Class Mail to the United States Patent and Trademark Office on April 16, 2004: Transmittal Letter, including Certificate of First Class Mailing under 37 C.F.R. 1.8; Information Disclosure Statement under 37 CFR §1.97(b); Information Disclosure Statement by Applicant (Form PTP/SB/08B); Copies of all cited references; and, A postage-paid return postcard itemizing the above documents.

Judy Sigal

Enclosures/GP:1574149 v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Frey II, William H. *et. al.*

Application Number

09/844,450

Filing Date

April 27, 2001

For:

**METHODS AND COMPOSITIONS
FOR ENHANCING CELLULAR
FUNCTION THROUGH
PROTECTION OF TISSUE
COMPONENTS**

Art Unit

1623

Examiner

Mcintosh III, Travis C.

File No.:

83935

**Information Disclosure Statement
Under 37 CFR §1.97(b)**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Form PTP/SB/08A is enclosed. Please consider these references in the examination of this application.

Sincerely,

Peter Forrest

Registration No. 33,235


Attorney for Applicants

04/20/2004 HBERHE 00000008 500937 09844450

01 FC:1806 180.00 DA

April 16, 2004

GP:1574147 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTP/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/844,450
				Filing Date	April 27, 2001
				First Named Inventor	Frey II, William H.
				Group Art Unit	1623
				Examiner Name	Mcintosh III, Travis
Sheet	2	of	2	Attorney Docket Number	83935

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C	FAWCETT, John R. et. al.; "Brain Research 850 (2002) 10-20: Research Report: Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants"; Elsevier Science B.V.; www.elsevier.com/locate/bres; US 2002.	
	D	KORNBERG, Arthur, et. al.; "Inorganic Polyphosphate: A Molecule of Many Functions"; Annual Review Biochemistry, Vol 68: 89 – 125; Annual Reviews; US 1999.	
	E	FREY II, William H. et. al.; "Brain Research 714 (1996) 87 - 94: Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor"; Elsevier Science B.V.; US 1996.	
	F	FREY II, William H. et. al.; "Brain Research 655 (1994) 153 - 160: Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain"; Elsevier Science B.V.; US 1994.	
	G	HOMER JR., Homer D. et. al.; "Brain Research 764 (1997) 93 - 100: Heme from Alzheimer's brain inhibits muscarinic receptor binding via thyl radical generation"; Elsevier Science B.V.; US 1997.	
	H	BORDAYO, Elizabeth, et al.; "Bilirubin, Myricetin and Carnosol Protect the Human Brain Muscarinic Acetylcholine Receptor from Free Radical Damage"; Alzheimer's Research Center; US – unknown.	
	I	FAWCETT, John R. et al.; "The Human Brain Muscarinic Acetylcholine Receptor is Inactivated by Free Radicals Produced by a Low Molecular Weight Endogenous Inhibitor from Alzheimer's Brain"; Alzheimer's Research Center; US – unknown.	
	J	OTTERBEIN, Leo E. et al.; "Invited Review: Heme oxygenase: colors of defense against cellular stress"; The American Physiological Society; www.ajplung.org; US 2000.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patents, Washington, DC 20231.